未登录

P

Paul J. Pockros

University of California System

H指数:64

被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lessons From COBALT: Will the Bell Also Toll for Thee?

从COBALT中汲取的教训：钟声也会为你而鸣吗？

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2024-10-020

PRE

Successful Use of Dupilumab for Eosinophilic Esophagitis in a Patient With Wilson's Disease

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2024-10-010

PRE

Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study

maralixibat在原发性硬化性胆管炎成人患者中的安全性，耐受性和有效性: 开放标签试点研究

HEPATOLOGY COMMUNICATIONS

IF4.6

2023-06-0117

OAAI

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

HEPATOLOGY COMMUNICATIONS

IF4.6

2020-12-2234

OAAI

Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2020-08-1912

PREAI

Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

IF12

2020-05-0168

OAAI

Don't Stop Post-Sustained Virologic Response Hepatocellular Carcinoma Surveillance Just Yet!

CLINICAL INFECTIOUS DISEASES

IF7.3

2019-11-220

PREAI

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

对照: 奥贝胆酸和阿托伐他汀对非酒精性脂肪性肝炎患者脂蛋白的随机2期研究

LIVER INTERNATIONAL

IF5.2

2019-09-10130

PREAI

Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis

JOURNAL OF HEPATOLOGY

IF33

2019-04-010

PREAI

A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis

HEPATOLOGY COMMUNICATIONS

IF4.6

2019-02-0157

OAAI

Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

DIGESTIVE AND LIVER DISEASE

IF3.8

2019-02-012

PREAI

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

KIDNEY INTERNATIONAL REPORTS

IF5.7

2019-02-015

OAAI

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

KIDNEY INTERNATIONAL REPORTS

IF5.7

2019-02-0121

OAAI

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

IF12

2018-11-0118

OAAI

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct Acting Antivirals for Hepatitis C

HEPATOLOGY COMMUNICATIONS

IF4.6

2018-09-2151

OAAI

Analysis of Differentially Expressed Proteins in Hepatocellular Carcinoma

TRANSPLANTATION

IF5

2018-07-011

PREAI

Editorial: chronic hepatitis B combination therapy-emerging success as proof-of-concept for future hepatitis B eradication?

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2018-05-170

OAAI

Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

JOURNAL OF HEPATOLOGY

IF33

2018-04-015

PREAI

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis

LIVER INTERNATIONAL

IF5.2

2018-03-3127

PREAI

SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS INFECTION GENOTYPE 1 AND 6 AND CHRONIC KIDNEY DISEASE: AN INTEGRATED ANALYSIS

GASTROENTEROLOGY

IF25.1

2017-04-014

PREAI